<?xml version="1.0" encoding="UTF-8"?>



<records>

  <record>
    <language>eng</language>
          <publisher>Oriental Scientific Publishing Company</publisher>
        <journalTitle>Biomedical and Pharmacology Journal</journalTitle>
          <issn>0974-6242</issn>
            <publicationDate>2026-11-09</publicationDate>
    
        <volume>19</volume>
        <issue>4</issue>

 
    <startPage></startPage>
    <endPage></endPage>

	    <publisherRecordId>74129</publisherRecordId>
    <documentType>article</documentType>
    <title language="eng">Rational In Silico Design of a Multi-Epitope Peptide Vaccine Targeting SPP1 for  Non-Small Cell Lung Cancer</title>

    <authors>
	 


      <author>
       <name>Yamuna Annadurai</name>

 
		
	<affiliationId>1</affiliationId>
      </author>
    

	 


      <author>
       <name>Murugesh Easwaran</name>


		
	<affiliationId>2</affiliationId>

      </author>
    

	 


      <author>
       <name>Prabhu Dhamodharan</name>

		
	<affiliationId>3</affiliationId>
      </author>
    

	 


      <author>
       <name>Shanmughavel Piramanayagam</name>

		
	<affiliationId>4</affiliationId>
      </author>
    


	 


      <author>
       <name>Luke Elizabeth Hanna</name>

		
	<affiliationId>5</affiliationId>
      </author>
    


	
    </authors>
    
	    <affiliationsList>
	    
		
		<affiliationName affiliationId="1">Central Research Laboratory for Biomedical Research, Vinayaka Mission’s Medical College and Hospital, Vinayaka Mission’s Research Foundation (VMRF-DU), Karaikal, India</affiliationName>
    

		
		<affiliationName affiliationId="2">Department of Bioinformatics, Bharathiar University, Coimbatore, India</affiliationName>
    
		
		<affiliationName affiliationId="3">Department of Biotechnology, Center for Drug Discovery, Karpagam Academy of Higher Education, Coimbatore, India</affiliationName>
    
		
		<affiliationName affiliationId="4">Department of Botany, Bharathiar University, Coimbatore, India</affiliationName>
    
		
		<affiliationName affiliationId="5">Department of Virology and Biotechnology, ICMR-National Institute for Research in Tuberculosis, Chennai, India</affiliationName>
    
		
	  </affiliationsList>






    <abstract language="eng">Lung cancer is defined as the exponential growth of mutated cells. Significantly, It is noteworthy because it is the second most prevalent kind of cancer in both men and women. Eighty-five percent of lung cancer fatalities are caused by non-small cell lung cancer (NSCLC). Immunotherapy has been shown to improve patient health, including survival rate, progression-free survival, and percentage of response. Peptides are more effective than antibodies at penetrating tissue and internalizing cells, thereby facilitating more effective delivery of immunomodulators to tumors. A multi-epitope peptide vaccine was designed to function as an antigen and elicit an immune response against NSCLC in response to natural immunity. The immunization with the peptide is expected to be more specific and efficient as the target protein is highly expressed in the worldwide NSCLC patient samples. We employed a set of computational tools and software, such as the IEDB database for epitope mapping, ToxinPred for Toxicity, AllerTop for allergenicity and vaxijen for antigenicity, Cluspro for molecular docking, C-ImmSim for molecular dynamics, and for the construction and validation of peptides. As a result, the generated multi-epitope peptide vaccine with favorable weighted score (-1168.7 kcal/mol) with TLR4. Immune simulation analysis indicates that the immunization response enhances the population of dendritic cells, NK cells, memory cells, B-cell differentiation, and immunoglobulin accumulation. In-silico analysis on cloning and expression of the 11-epitope vaccine construct with pET-28a(+) vector in <em>Escherichia coli</em> (Strain K12) showed high potency with a Codon Adaptation Index value of 1.0. This study presents the<em> in-silico </em>design of a peptide vaccine with 11-epitopes, incorporating CTL (4 epitopes), HTL (1 epitope), and B-cell (2 epitopes) complemented by T-cell epitopes (4 epitopes), targeting the SPP1 antigen for NSCLC immunotherapy. The vaccine construct demonstrated favorable antigenicity (probable antigen, VaxiJen score &gt;0.4) with non-allergenic, and non-toxic properties.</abstract>

    <fullTextUrl format="html">https://biomedpharmajournal.org/vol19no4/rational-in-silico-design-of-a-multi-epitope-peptide-vaccine-targeting-spp1-for-non-small-cell-lung-cancer/</fullTextUrl>

<keywords language="eng">

      
        <keyword>Epitope</keyword>
      

      
        <keyword> Immunotherapy</keyword>
      

      
        <keyword> In-Silico cloning</keyword>
      

      
        <keyword> NSCLC</keyword>
      

      
        <keyword> Peptide</keyword>
      

      
        <keyword> Vaccine construct</keyword>
      
</keywords>
  </record>
</records>